Patient P-02633

Synthetic patientMETA-24 · Day 151 · 35–44 · M · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −17% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 73 SC-12 recommended — Supportive Compound SC-12
Day 74 Patient accepted — Started SC-12 in the companion
Day 80 GI symptom burden −15% vs expected — Supportive Compound SC-12
Day 86 Tolerance state changed — Unstable → Improving
Day 87 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 87.

Primary contributors, last 14 days

GI instability+14
Toxicity-9
Inflammatory activity+5
Treatment adherence-3
Nutritional resilience-2

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −17%
Supportive Compound SC-12Day 73
Result: symptom burden −15%

LIFE OS recommendation

GI Support Protocol GI-04

87%

probability of meaningful tolerance improvement

284 similar trajectories
86% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 52 and rising
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
- WearableHRV 20 ms, trending down
Autonomic recovery ↓40
- Wearable2,480 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 47/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 19 ms
Sleep: 6.5 h
Steps: 2,600
Resting HR: 69 bpm

Daily log: GI score 52, nutritional resilience 43, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02363	56%	S14	GI-04	improved	49
P-02574	56%	S14	ME-01	improved	45
P-02002	54%	S14	GI-04	improved	47
P-02035	54%	S19	GI-04	improved	53
P-02014	51%	S14	GI-04	improved	48
P-02118	51%	S14	GI-04	improved	47
P-02125	49%	S14	GI-04	improved	55
P-02108	48%	S14	GI-04	improved	43
P-02159	47%	S14	GI-04	improved	47
P-02241	47%	S09	GI-04	improved	56
P-02648	47%	S14	SC-12	improved	47
P-02185	46%	S14	GI-04	improved	51